Barclays analyst Etzer Darout raised the firm’s price target on Kura Oncology (KURA) to $28 from $11 and keeps an Overweight rating on the shares. The firm cites the ziftomenib approval for the target increase.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- FDA Calendar: These Are the Upcoming FDA Drug Approvals
- Kura Oncology price target raised to $30 from $29 at BofA
- Kura Oncology price target raised to $38 from $36 at Wedbush
- Kura Oncology price target raised to $16 from $14 at UBS
- Kura Oncology’s Strategic Positioning and FDA Approval of Komzii Boosts Buy Rating